Ww. Hochreiter et al., Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions, UROLOGY, 56(6), 2000, pp. 1025-1029
Objectives. Chronic prostatitis/chronic pelvic pain syndrome (CPPS) is a di
sorder characterized by pelvic pain and varying degrees of inflammation exh
ibited in expressed prostatic secretions (EPS). To provide objective parame
ters of inflammation, we measured the cytokines interleukin 8 (IL-8) and ep
ithelial neutrophil activating peptide 78 (ENA-78) in EPS of healthy men, m
en with benign prostatic hyperplasia (BPH), men with bacterial prostatitis
(BP), and men with chronic prostatitis/CPPS.
Methods. Enzyme-linked immunosorbent assays of the EPS for IL-8 and ENA-78
were done in 63 men: control (n = 9), BPH (n = 6), BP (n = 3), inflammatory
CPPS (National Institutes of Health [NIH] category IIIa) (n = 17), noninfl
ammatory CPPS (NIH category IIIb) (n = 17), and asymptomatic inflammatory p
rostatitis (NIH category IV) (n = II).
Results. IL-8 was detectable in all patients, and ENA-78 was detectable in
all except 2 patients (threshold of detection 10 pg/mL for IL-8, 15 pg/mL f
or ENA-78). Mean levels of IL-8 [ENA-78] were similar in control (3010 pg/m
L [423 pg/mL]), BPH (3341 pg/mL [98 pg/mL]), and IIIb (2751 pg/mL [335 pg/m
L]) groups. Both cytokine levels were higher in BP (11,175 pg/mL [13,761 pg
/mL]), IIIa (10,418 pg/mL [2240 pg/mL]), and IV (8571 pg/mL [1865 pg/mL]) g
roups. A statistically significant difference between the control group ver
sus BP, IIIa, and IV (P <0.05) groups was found for IL-8 but not for ENA-78
.
Conclusions. IL-8 and ENA-78 are frequently elevated in the EPS of men with
BP, CPPS IIIa, and asymptomatic inflammatory prostatitis category IV. Thes
e cytokines are direct mediators of leukocyte accumulation and activation a
t inflammatory sites and may be responsible, in part, for the presence of i
nflammatory reaction in the prostate. UROLOGY 56: 1025-1029, 2000. (C) 2000
, Elsevier Science Inc.